May 7, 2020
HighTide phase 2a Study of HTD1801 in NASH Patients meets primary endpoint
HighTide Therapeutics said that its HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes, as HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors.